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Background: We evaluated the association of pulse pressure (PP) and
different antiplatelet regimes with clinical and safety outcomes in an
all-comers percutaneous coronary intervention (PCI) population.
Methods: In this analysis of GLOBAL LEADERS (n ¼ 15,936) we
compared the experimental therapy of 23 months of ticagrelor after 1Received for publication August 21, 2019. Accepted October 14, 2019.
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Contexte : Nous avons evalue l’association entre la pression
differentielle (PD), differents schemas antiplaquettaires et les resultats
cliniques et les resultats relatifs à l’innocuite dans une population de
patients de tous types ayant subi une intervention coronarienne
percutanee (ICP).Pulse pressure (PP) is the pulsatile component of blood
pressure (BP) and can predict cardiovascular outcomes.1 A rise
in PP, which is mainly observed in middle-aged and elderly
patients owing to an increase in systolic BP (SBP) and
decrease in diastolic BP (DBP), is considered to be a marker of
underlying vascular disease and reflects a reduction in arterial
compliance.2 Specifically, in patients with coronary artery
disease (CAD), aortic PP predicts major adverse cardiovascularll rights reserved.
month of dual-antiplatelet therapy (DAPT) versus standard DAPT for 12
months followed by aspirin monotherapy in subjects who underwent
PCI and were divided into 2 groups according to the median PP (60
mm Hg). The primary end point (all-cause death or new Q-wave
myocardial infarction) and the composite end points: patient-oriented
composite end points (POCE), Bleeding Academic Research Con-
sortium (BARC) 3 or 5, and net adverse clinical events (NACE) were
evaluated.
Results: At 2 years, subjects in the high-PP group (n ¼ 7971) had
similar rates of the primary end point (4.3% vs 3.9%; P ¼ 0.058), POCE
(14.9% vs 12.7%; P ¼ 0.051), and BARC 3 or 5 (2.5% vs 1.7%;
P ¼ 0.355) and higher rates of NACE (16.4% vs 13.7%; P ¼ 0.037)
compared with the low-PP group (n ¼ 7965). Among patients with PP
< 60 mm Hg, the primary end point (3.4% vs 4.4%, adjusted hazard
ratio [aHR] 0.77, 95% confidence interval [CI] 0.61-0.96), POCE
(11.8% vs 13.5%, aHR 0.86, 95% CI 0.76-0.98), NACE (12.8% vs
14.7%, aHR 0.85, 95% CI 0.76-0.96), and BARC 3 or 5 (1.4% vs 2.1%,
aHR 0.69, 95% CI 0.49-0.97) were lower with ticagrelor monotherapy
compared with DAPT. The only significant interaction was for BARC 3
or 5 (P ¼ 0.008).
Conclusions: After contemporary PCI, subjects with high PP levels
experienced high rates of NACE at 2 years. In those with low PP,
ticagrelor monotherapy led to a lower risk of bleeding events
compared with standard DAPT.
Methodologie : Dans cette analyse des donnees de l’etude GLOBAL
LEADERS (n ¼ 15 936), nous avons compare le traitement experi-
mental de 23 mois par le ticagrelor après 1 mois de bitherapie anti-
plaquettaire (BTAP) et la BTAP standard de 12 mois suivie de
l’administration d’acide acetylsalicylique en monotherapie chez des
sujets ayant subi une ICP, qui avaient ete divises en deux groupes en
fonction de la PD mediane (60 mmHg). Le critère d’evaluation prin-
cipal (decès toutes causes ou nouvel infarctus du myocarde avec onde
Q) et les critères d’evaluation secondaires composites (critères
d’evaluation composites axes sur le patient [POCE, patient-oriented
composite endpoints], classification 3 ou 5 du BARC [Bleeding Aca-
demic Research Consortium] et evenements indesirables cliniques
nets [NACE, net adverse clinical events]) ont ete evalues.
Resultats : À 2 ans, les sujets presentant une PD elevee (n ¼ 7 971)
affichaient des taux similaires à l’egard du critère d’evaluation prin-
cipal (4,3%vs3,9%;p¼0,058), desPOCE (14,9%vs12,7%;p¼0,051)
et de la classification 3 ou 5 du BARC (2,5 % vs 1,7 %; p¼ 0,355), ainsi
que des taux plus eleves de NACE (16,4 % vs 13,7 %; p ¼ 0,037)
comparativement aux sujets presentant une PD faible (n ¼ 7965).
Chez les patients ayant une PD < 60 mm Hg, les taux du critère
d’evaluation principal (3,4 % vs 4,4 %; rapport des risques instantanes
corrige [RRIc] : 0,77; intervalle de confiance [IC] à 95 % : 0,61 e 0,96),
des POCE (11,8 % vs 13,5 %; RRIc : 0,86; IC à 95 % : 0,76 e 0,98), du
critère NACE (12,8 % vs 14,7 %; RRIc : 0,85; IC à 95 % : 0,76e 0,96) et
de la classification 3 ou 5 du BARC (1,4 % vs 2,1 %; RRIc : 0,69; IC à
95 % : 0,49 e 0,97) etaient moins eleves dans le groupe traite par le
ticagrelor en monotherapie que dans le groupe sous BTAP. Seule
l’interaction avec la classification 3 ou 5 du BARC etait significative
(p ¼ 0,008).
Conclusions : Après une ICP courante, les sujets presentant une PD
elevee ont affiche des taux de NACE plus eleves à 2 ans. Chez les
patients presentant une PD faible, le traitement par le ticagrelor en
monotherapie a ete associe à un risque inferieur d’hemorragie com-
parativement à la BTAP standard.
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Volume - 2019events and all-cause mortality3 and provides additional prog-
nostic information beyond mean BP.4 Brachial PP levels were
also independently associated with all-cause mortality in CAD
patients after percutaneous coronary intervention (PCI) at 5-
year follow-up.5 Recently, a retrospective study demonstrated
that the combination of high SBP and low DBPda wide
PPdbefore PCI is associated with myocardial infarction and
stroke at 1 year after the procedure.6 Although previous
studies have reported PP predicting poor clinical outcomes
after PCI, they were mainly conducted in registries with
outdated PCI approaches (balloon angioplasty and bare metal
stent implantation) in selected PCI population. Thus, data on
PP association with outcomes in clinical trials including a large
all-comers population with CAD who have undergone
contemporary PCI are lacking.
Recently, the GLOBAL LEADERS trial showed that 23-
month ticagrelor monotherapy following 1-month dual-
antiplatelet therapy (DAPT) was not superior to standard
DAPT in preventing the primary end pointdall-cause mor-
tality or new Q-wave myocardial infarction (MI)damong all-
comer patients 2 years after PCI.7 Rates of the secondary
composite end points major bleeding (type 3 or 5 according to
Bleeding Academic Research Consortium [BARC]),7 patient-
oriented composite end points (POCE), and net adverse
clinical events (NACE), which combines POCE and bleedingevents,8 were also similar between the 2 antiplatelet strategies.
Nonetheless, ticagrelor monotherapy was shown to be effec-
tive and safe.7
In the present analysis of the GLOBAL LEADERS trial,
which enrolled a large “real-life” population, we sought to
evaluate (1) the association of PP with clinical outcomes after
contemporary PCI, and (2) the impact of different antiplatelet
strategies on the 2-year clinical and safety outcomes in all-
comer patients who underwent PCI stratified by low and
high PP.Methods
The trial
This study is a subanalysis of the GLOBAL LEADERS
trial (ClinicalTrials.gov registration number NCT01813435)
which is described in detail elsewhere.7,9 In brief, the trial was
a randomized, open-label, multicenter superiority study
designed to compare 2 antiplatelet therapy strategies in all-
comer patients after PCI with a biolimus A9eeluting stent.
The experimental therapy comprised aspirin (75-100 mg)
daily plus ticagrelor (90 mg) twice daily for 1 month, followed
by 23 months of ticagrelor monotherapy, and the reference
therapy was standard DAPT with aspirin (75-100 mg) daily
Table 1. Baseline clinical characteristics according to pulse pressure (PP) group, n (%)
Characteristic PP < 60 mm Hg (n ¼ 7965) PP  60 mm Hg (n ¼ 7971) P value
Age, mean (SD) 62.08  10.29 66.99  9.73 < 0.001
BMI, mean (SD) 28.16  4.54 28.22  4.65 0.422
Diabetes mellitus 1736 (21.8) 2294 (28.8) < 0.001
Insulin-dependent diabetes mellitus 481 (6.1) 740 (9.3) < 0.001
Male 6427 (80.7) 5799 (72.8) < 0.001
Hypertension 5375 (67.7) 6322 (79.5) < 0.001
Hypercholesterolemia 5263 (68.3) 5490 (71.1) < 0.001
Smoking history 2397 (30.1) 1765 (22.1) < 0.001
Peripheral vascular disease 392 (5.0) 608 (7.7) < 0.001
COPD 392 (4.9) 429 (5.4) 0.197
History of bleeding 50 (0.6) 48 (0.6) 0.919
Renal failure 895 (11.3) 1272 (16.0) < 0.001
Previous stroke 197 (2.5) 224 (2.8) 0.199
Previous MI 1937 (24.4) 1764 (22.2) 0.001
Previous PCI 2565 (32.2) 2640 (33.2) 0.218
Previous CABG 405 (5.1) 533 (6.7) < 0.001
Clinical presentation < 0.001
Stable CAD 3866 (48.5) 4592 (57.6)
Unstable angina 1026 (12.9) 994 (12.5)
NSTEMI 1818 (22.8) 1549 (19.4)
STEMI 1255 (15.8) 836 (10.5)
Medication use at discharge
ACE inhibitors 4838 (61.2) 4721 (59.7) 0.054
Angiotensin II receptor blockers 1156 (14.6) 1494 (18.9) < 0.001
b-Blockers 6351 (80.3) 6202 (78.4) 0.004
Statins 7426 (93.8) 7244 (91.5) < 0.001
ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; MI, myocardial infarction; NSTEMI, noneST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention;
STEMI, ST-segment-elevation myocardial infarction.
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Association of Pulse Pressure and PCI Outcomesplus either clopidogrel (75 mg ) daily (for patients with stable
coronary artery disease) or ticagrelor (90 mg) twice daily (for
patients with acute coronary syndrome [ACS]) for 12 months,
followed by aspirin monotherapy for 12 months.7,9
The trial was approved by the Institutional Review Board
at each participating institution. The study was performed in
accordance with the ethical principles for medical research
involving human subjects of the World Medical Association
(Declaration of Helsinki), the International Conference of
Harmonization, and Good Clinical Practice. Every participant
provided written informed consent at enrollment. An inde-
pendent data and safety monitoring committee oversaw the
safety of all patients.
Study population
The main study enrolled 15,991 patients from July 2013
to November 2015 in an “all-comers” design, ie, no restriction
regarding clinical presentation, complexity of the lesions, or
number of stents used. Because 23 patients withdrew consent
and requested data deletion from the database and 32 subjects
had systolic and diastolic BP levels equal to zero (treated as
mistakes in completion of the electronic case report form and
then excluded), a total of 15,936 subjects remained for this
analysis (99.65% of all randomized patients).
Pulse pressure
PP was calculated by subtracting the DBP from the SBP
recorded at the time of randomization from a single seated BP
measurement. Patients were then divided into 2 groups ac-
cording to the median PP of 60 mm Hg into the low
(PP < 60 mm Hg) and high (PP  60 mm Hg) groups.Study end points
In this subanalysis of the GLOBAL LEADERS trial we
evaluated the association of PP and different antiplatelet
strategies with the primary end pointda composite of
investigator-reported all-cause mortality or nonfatal new Q-
wave MI identified by an independent electrocardiography
(ECG) core laboratory7dat 2 years in all-comer subjects
who underwent PCI and were stratified by low or high
baseline PP. Secondarily, we assessed the interaction of these
antiplatelet therapies on the key secondary safety end point
site-reported bleeding assessed according to the BARC
criteria (grade 3 or 5, as detailed in Supplemental
Table S1),10 the POCE, and NACE at 2 years in the PP
groups. POCE was defined according to the recent Aca-
demic Research Consortium 2 consensus as all-cause mor-
tality, any stroke (ischemic and hemorrhagic), any MI
(including periprocedural or spontaneous with ST-segment-
elevation MI [STEMI] or noneST-segment-elevation
myocardial infarction [NSTEMI]), and any revascularization
(re-PCI or coronary artery bypass graft surgery [CABG] in
target or nontarget vessels).11 NACE was defined as the
combination of clinically relevant ischemic events (POCE)
and safety-related bleeding events (BARC 3 or 5). The
composite end points were analyzed according to timeetoe
first event analysis.
Statistical analyses
Continuous variables are expressed as mean  SD and
were compared by means of independent t test. Categoric
variables are presented as n (%) and were compared with the
use of Fisher exact test if dichotomous or chi-square test if > 2
Table 2. Clinical and safety outcomes at 2 years according to pulse pressure (PP) groups
Outcomes at 2 years
PP < 60 mm Hg
(n ¼ 7965)
PP  60 mm Hg
(n ¼ 7971)
Unadjusted HR
(95% CI) P value
Adjusted HR*
(95% CI) p value
Death/Q-wave MI 309 (3.9) 342 (4.3) 1.11 (0.95-1.29) 0.190 0.86 (0.73-1.01) 0.058
POCE 1001 (12.7) 1172 (14.9) 1.19 (1.09-1.29) < 0.001 1.09 (1.00-1.19) 0.051
BARC 3 or 5 136 (1.7) 195 (2.5) 1.44 (1.16-1.79) 0.001 1.11 (0.89-1.40) 0.355
NACE 1083 (13.7) 1290 (16.4) 1.21 (1.12-1.31) < 0.001 1.09 (1.01-1.19) 0.037
Data are presented as number of events with Kaplan-Meier estimates in parentheses.
BARC, Bleeding Academic Research Consortium; Death/Q-wave MI, composite of all-cause mortality or nonfatal new Q-wave myocardial infarction; NACE:
net adverse clinical events; POCE, patient-oriented composite end points.
* Adjusted for age, diabetes, sex, hypertension, peripheral vascular disease, renal failure, history of myocardial infarction, history of coronary artery bypass
grafting, and presentation of acute coronary syndrome.
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cumulative rates of events, and log-rank test was performed to
examine the differences between groups. The outcomes ac-
cording to PP group were assessed with the use of univariate
and multivariate Cox proportional hazards models. The
covariates in the multivariate model were included based on
clinical relevance as well as factors associated with PP in
previous studies, such as age, diabetes, sex, hypertension,
peripheral vascular disease, renal failure, history of MI, history
of CABG, and presentation of ACS. Hazard ratio (HR) and
95% confidence intervals (CIs) were calculated, and interac-
tion test was performed to evaluate the differences in the
treatment effect of antiplatelet strategies in PP groups. Asso-
ciation between the continuous PP levels and clinical (POCE)
and safety bleeding (BARC 3 or 5) outcomes were assessed
with the use of spline function in the Cox regression analysis.
All of the analyses were performed according to the intention-
to-treat principle of all randomized patients as time to first
event. A 2-sided alpha of 5% was considered to be
statistically significant. The analyses were performed in
R version 3.4.2.Results
Baseline clinical characteristics
Out of 15,936 subjects who remained in this subanalysis of
the GLOBAL LEADERS trial, 7,965 had a low PP (< 60 mm
Hg) and 7,971 had a high PP ( 60 mm Hg). As expected,
those in the high PP group were older and more likely to be
women, diabetic (and insulin users), hypertensive, and hy-
percholesterolemic compared with their low-PP counterparts.
In addition, the high-PP group had a higher proportion of
patients with peripheral vascular disease, renal failure, previous
CABG, and stable CAD compared with patients in the low-
PP group. On the other hand, compared with the high-PP
group, patients in the low-PP group were more commonly
smokers and more likely to present with an NSTEMI or
STEMI (Table 1).
Association of pulse pressure levels with clinical
outcomes
As presented in Table 2 in the univariate model, at 2 years,
rates of primary end pointdthe composite of all-cause
mortality or nonfatal new Q-wave MIdwere similar be-
tween the PP groups, whereas POCE, NACE, and BARC
3 or 5 occurred more frequently in the group withPP  60 mm Hg. Multivariate analyses revealed that patients
in the high-PP group had significantly higher rates of NACE,
although POCE and the primary end point were higher
without reaching statistical significance, compared with the
patients in the low-PP group. In the multivariate model, rates
of BARC 3 or 5 bleeding were similar between the PP groups
(Table 2). Spline representation of the HRs of different
continuous PP levels for POCE and BARC 3 or 5 are shown
in Figure 1.
Impact of antiplatelet strategies on clinical and safety
outcomes
No treatment effect of ticagrelor monotherapy compared
with standard DAPT was observed among patients with high
PP for the studied outcomes. On the other hand, subjects
with aow PP treated with ticagrelor had a lower risk of the
clinical and safety outcomes assessed in this subanalysisdthe
primary end point, POCE, NACE, and BARC 3 or
5dcompared with standard DAPT (Fig. 2). Interaction
testing revealed differences in the treatment effect of anti-
platelet strategies between PP groups regarding the secondary
safety outcome onlydBARC 3 or 5 bleeding eventsdP ¼
0.008 (Fig. 2). Timeetoefirst event curves for the secondary
end points and interaction with the antiplatelet strategies are
shown in Figure 3.Discussion
The main findings of this subanalysis of the GLOBAL
LEADERS trial are that (1) at 2 years’ follow-up, regardless of
confounders, patients with high PP have higher rates of
NACE compared with those with low PP, and (2) a significant
interaction was observed between the antiplatelet strategies
and PP groups at 2 years for safety: Ticagrelor monotherapy
reduced BARC 3 or 5 bleeding compared with standard
DAPT in subjects with low PP, but not in those with high PP.
Given the trial design, our study is the first to examine the
interaction between PP and antiplatelet scheme on ischemic
and safety outcomes in an all-comers population after
contemporary PCI.
Studies have clearly pointed out that cardiovascular risk is
related not only to an increase in SBP but also to a decrease in
DBP. Because both components of BP tend to diverge after
the age of 55 years,12 PP has emerged as an important risk
factor for predicting cardiovascular events.1,13 PP increases
along with age, body mass index, cholesterol, and risk of
diabetes, but independently from these risk factors it has been
Figure 1. Spline representation of the unadjusted hazard ratios for patient-oriented composite end points (POCE) and major bleeding (Bleeding
Academic Research Consortium 3 or 5) at 2 years according to pulse pressure values.
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Association of Pulse Pressure and PCI Outcomesshown to be a strong predictor of death from cardiovascular
disease, with an increased risk of 10% in individuals 46-77
years old per 10 mm Hg increment in PP.14 On the other
hand, rises in PP, which reflect a reduction in arterial
compliance, have been identified as a simple marker of un-
derlying vascular disease.2 This raises the hypothesis that PP
may participate as either a direct risk factor for cardiovascular
events or a marker of poor outcome.
Adverse outcomes in patients with CAD have been asso-
ciated with elevated PP. Ascending aortic PP normalized to
the mean BP correlated with the extent of coronary athero-
sclerosis regardless of the presence of hypertension,15 and was
able to predict the risk of major adverse cardiovascular events
and all-cause mortality3 in individuals with angiographicallyFigure 2. Forest-plot representation of ischemic and safety outcomes at 2 ye
groups. Data shown are number of events with Kaplan-Meier estimates in par
peripheral vascular disease, renal failure, history of myocardial infarction,
coronary syndrome. BARC, Bleeding Academic Research Consortium; Death
myocardial infarction; NACE: net adverse clinical events; POCE, patient-orieproven CAD. Specifically in CAD patients after PCI, mean
BP-normalized PP was a powerful predictor of restenosis 3
months after the procedure (odds ratio 33.5, 95% CI 2.04-
550.6, for the highest, compared with the lowest, tertile of
PP).16 Brachial PP levels were also independently associated
with total mortality (relative risk 1.08, 95% CI 1.01-1.15, per
10 mm Hg increment in PP) in coronary patients followed for
5 years after revascularization.5 Furthermore, increased
noninvasive heart rateecorrected aortic amplification index,
which assesses arterial stiffness,17,18 predicted the occurrence
of the combination of death, MI, and clinical restenosis in
CAD patients within 2 years after PCI.19 Of course, these
studies linking restenosis to PP were done in a time when the
rate of restenosis was higher than currently. Most recently, aars according to antiplatelet therapies in different pulse pressure (PP)
entheses. Hazard ratios adjusted for age, diabetes, sex, hypertension,
history of coronary artery bypass grafting and presentation of acute
/Q-wave MI, composite of all-cause mortality or nonfatal new Q-wave
nted composite end points.
Figure 3. (A) Interaction of the 2 antiplatelet therapies on the clinical patient-oriented composite end points in the different pulse pressure (PP)
groups. (B) Interaction of the 2 antiplatelet therapies on the safety end point Bleeding Academic Research Consortium 3 or 5 in the different PP
groups. (C) Interaction of the 2 antiplatelet therapies on the combination of clinically relevant ischemic events and safety-related bleeding events in
the different PP groups.
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Association of Pulse Pressure and PCI Outcomeslarge retrospective analysis associated higher preprocedural PP
(high SBP combined with low DBP) with a higher incidence
of MI and stroke at 1 year after PCI.6 Our findings are in part
consistent with those previous studies. We found that after
adjusting for several confounders, subjects with high baseline
PP who underwent PCI were at an increased risk (9% risk
increase along the 2 years) of having the combination of
clinically relevant ischemic events and safety-related bleeding
events, namely NACE. Of the components of NACE, safety-
related bleeding (BARC 3 or 5) has previously been poorly
explored in relation to baseline PP in subjects undergoing
PCI. The present study supports the prognostic importance of
PPdwhich reflects increased arterial stiffnessdon subsequent
cardiovascular outcomes and bleeding events in patients
after PCI.
The pathophysiology of the effects of increased PP is
complex. It causes increased cyclic stretch of vascular struc-
tures activating several signalling pathways ultimately leading
to atherosclerotic remodelling, proinflammatory cell migra-
tion, and increased oxidative stress.20 A bidirectional link is
also present: Whereas on one hand elevated PP mediates
progression of atherosclerosis, on the other hand plaque
formation impairs the elastic properties of the arterial wall,
elevating PP and creating a vicious cycle.20-22 Pulsatile BP
has been implicated as the main mechanism causing insta-
bility and rupture of atherosclerotic plaque, and conse-
quently acute coronary syndrome and other vascular
complications.23,24 In fact, studies have suggested that car-
diac events are more related to the pulsatile stress of large-
artery stiffness during systoledas reflected by a rise in
PPdthan the steady-state stress of small-vessel resistance
during diastole (as reflected in rises in both SBP and
DBP).25 Rises in aortic stiffness have also supported the link
between cardiac performance and myocardial perfusion. It
has been shown that among patients undergoing PCI,
compared with those with compliant aortas, those with stiffer
aortas had a lower hyperemic coronary blood flow response
to adenosine as well as a smaller improvement in hyperemic
coronary blood flow after a successful PCI.26 These data
demonstrate that, because the arterial wall continuously in-
teracts with hemodynamic forces, the PP, reflecting increased
arterial stiffness, might in part be the mechanical component
underlying adverse cardiovascular and bleeding events. It is
worth mentioning, however, that other potential contribu-
tors may be associated with the results we noted: PP could
be participating as either a simple marker of advanced
vascular disease or another underlying mechanism related to
our findings.
Another finding of this subanalysis of the GLOBAL
LEADERS trial was that prolonged ticagrelor monotherapy
was beneficial in reducing the risk of bleeding events
compared with conventional DAPT followed by aspirin alone
in subjects who had low PP, whereas no different effect was
observed between the therapies in those with high PP. Since
the relevant Platelet Inhibition and Patient Outcomes
(PLATO) trial27 revealed the superiority of ticagrelor over
clopidogrel in terms of the primary efficacy end point
apparently without an increase in the rate of major bleeding in
patients with ACS, protective effects of ticagrelor have been
extensively explored in the literature.28,29 These pleiotropic
effectsdmainly reported to be due to increasing adenosinelevels30-32dhave been associated with improvements in
endothelial function compared with clopidogrel28,29 and in-
creases in circulating endothelial progenitor cell levels (EPCs)
and decreases in proinflammatory cytokines compared with
prasugrel.33 In fact, studies have suggested that increasing
circulating EPCs in ACS subjects is critical to improving
vascular healing and regenerate endothelial homeostasis.34
Beyond its potency in inhibiting platelet aggregation, tica-
grelor seems to have additional vascular protective properties.
In light of these data, our study suggested that subjects who
underwent PCI and had a not yet high PP (< 60 mm Hg)d
reflecting a healthier profile of arterial compliancedwere the
target group who, possibly owing to ticagrelor-related pleio-
tropic effects, have a reduced risk of bleeding from ticagrelor
compared with DAPT. On the other hand, no effect of
ticagrelor on cardiovascular and bleeding events was notice-
able in the group with high PP, which is probably due to their
more advanced arterial stiffness. Although ticagrelor was not
found to be more effective than DAPT in reducing cardio-
vascular outcomes (P values for interaction were not signifi-
cant), its safety profile after PCI with low PP is of particular
importance.
Accordingly, antiplatelet therapy in individuals with high
BP who presented with either cardiovascular or cerebrovas-
cular disease has been associated with an increased risk for
hemorrhagic stroke.35-37 Nevertheless, recent guidelines for
the management of arterial hypertension,38 based mainly on a
Cochrane systematic review,39 state that for secondary pre-
vention the benefit of aspirin in patients with elevated BP is
many times greater than the harm (an absolute reduction in
vascular events of 4.1% compared with placebo). However,
antiplatelet agents such as ticlopidine, clopidogrel, and the
newer prasugrel and ticagrelor have not been sufficiently
evaluated in these hypertensive patients.38 Although our
findings showed similar rates of clinical and safety outcomes in
taking either ticagrelor or DAPT at 2-year follow-up in sub-
jects with high PP, future research is necessary to delineate
this relationship more precisely.
Limitations
The main limitation is that our subanalysis was exploratory
and not a prespecified analysis of the GLOBAL LEADERS
trial, so the results should be considered as hypothesis
generating. The trial did not have a clinical adjudication
committee for serious adverse events, owing to limited
financial resources. Except for the primary end pointdall-
cause death and new Q-wave MIdwhich was assessed by an
independent ECG core laboratory, the end points were site
reported. However, the trial was monitored for consistency
and reporting of events, and on-site monitoring visits were
regularly performed. We based our analyses on single office
BP measurement, but it would be more accurate and precise
to use the mean of multiple BP readings or ambulatory
monitoring. Central PP has been shown to predict cardio-
vascular events40 and to be associated with coronary athero-
sclerosis41 more strongly than peripheral PP, but aortic
measurements were not assessed in the trial. On the other
hand, the difference between central and peripheral PP
observed in younger individuals is not as evident as in the
elderly population42dwhich favours our findings on brachial
8 Canadian Journal of Cardiology
Volume - 2019PP evaluation because the population included in the
GLOBAL LEADERS trial had a mean age of 64.5 years.7
Nonetheless, a meta-analysis has supported that central PP
does not offer a significant increase over peripheral PP in
predictive ability for clinical events.43Conclusion
Subjects with high PP experienced higher rates of the
combination of clinically relevant ischemic events and safety-
related bleeding events (NACE) at 2 years after PCI compared
with those with low PP. In addition, ticagrelor monotherapy
was favourable to standard DAPT strategy in providing a
lower risk of bleeding events (BARC 3 or 5) in patients with
low PP. The results should be interpreted as hypothesis
generating; prospective confirmation of our results is needed.Funding Sources
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